Caplin Point Laboratories' Q1 FY 2025-26 Quarterly Results

Result Summary

• Caplin Point Laboratories Ltd reported a 13.4% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Jun (Q1 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 11.7%.
• Its expenses for the quarter were up by 7.5% QoQ and 8.0% YoY.
• The net profit increased 24.4% QoQ and increased 20.7% YoY.
• The earnings per share (EPS) of Caplin Point Laboratories Ltd stood at 20 during Q1 FY 2025-26.

Financial Statments for Q1 FY 2025-26

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Caplin Point Laboratories Ltd is a pharmaceutical company that primarily operates in the healthcare and pharmaceutical industry. The company is engaged in the development, manufacturing, and marketing of a range of pharmaceutical products. Caplin Point Laboratories is known for its focus on the production and distribution of generic medicines, including injectables, tablets, and other dosage forms. However, specific details about recent major developments or changes in the company's product lines or strategic direction are not available from the provided data. The company's operations are likely influenced by the broader trends and regulatory environment within the pharmaceutical industry.

Revenue

In the first quarter of the fiscal year 2026 (Q1FY26), Caplin Point Laboratories Ltd reported a total income of ₹533.36 crores. This represents a quarter-over-quarter (QoQ) increase of 13.4% from ₹470.51 crores in the fourth quarter of fiscal year 2025 (Q4FY25). Additionally, there was an 11.7% year-over-year (YoY) increase from ₹477.52 crores in the first quarter of fiscal year 2025 (Q1FY25). These figures indicate a period of revenue growth for the company, with both QoQ and YoY improvements in total income. The increase in total income is a critical metric for evaluating the company's ability to generate more revenue over time, reflecting its sales performance and market reach.

Profitability

Caplin Point Laboratories Ltd reported a profit before tax of ₹184.43 crores in Q1FY26, which is a 26.3% increase QoQ from ₹145.97 crores in Q4FY25 and a 19.5% increase YoY from ₹154.36 crores in Q1FY25. The profit after tax for Q1FY26 stood at ₹150.76 crores, reflecting a 24.4% QoQ increase from ₹121.23 crores in Q4FY25 and a 20.7% YoY growth from ₹124.92 crores in Q1FY25. The company's earnings per share (EPS) for Q1FY26 were ₹20.00, marking a QoQ growth of 25.8% from ₹15.90 in Q4FY25 and a YoY increase of 23.5% from ₹16.20 in Q1FY25. These metrics highlight a period of enhanced profitability for the company, as evidenced by the growth in profits and EPS.

Operating Metrics

The total expenses for Caplin Point Laboratories Ltd in Q1FY26 were ₹348.93 crores, which marks a 7.5% QoQ increase from ₹324.54 crores in Q4FY25 and an 8.0% YoY increase from ₹323.16 crores in Q1FY25. The tax expense for the company in Q1FY26 was ₹33.70 crores, showing a QoQ increase of 35.9% from ₹24.80 crores in Q4FY25 and a YoY rise of 14.4% from ₹29.46 crores in Q1FY25. These figures reflect the company's operational expenditures and tax liabilities, with notable increases in both areas over the previous quarters. The operating metrics provide insights into the company's cost structure and its management of operational expenses relative to its income growth.